Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death
US Regulator May Call For Limits
Executive Summary
The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.
You may also be interested in...
After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy
CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.
Astellas Pauses XLMTM Gene Therapy Trial After Another Safety Scare
The day before an FDA advisory committee meeting about the safety of AAV vector-based gene therapies, Astellas reported liver damage in a patient in its trial of AT132.
Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.